BioSpace News Archive

Avellino Lab USA, Inc. (Avellino) today announced full nationwide availability in the U.S. of AvaGen™, The Genetic Eye Test, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies.

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has received clearance from the Israeli Ministry of Health to commence a Phase IIb study

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced it has established a research and development center in Cambridge, Massachusetts, to pursue its mRNA-based gene editing and cellular therapies.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced financial results for the first quarter of 2021.

The President of Asclepius Meditec held a video conference call organized by the International Department of the Central Committee of CPC on May 26, 2021, to express his concerns to top Nepalese leaders and his willingness to donate 100 hydrogen oxygen generators to provide emergency support in the joint fight against COVID-19 in Nepal and in order to overcome difficulties together with close neighbors.

Kintara Therapeutics, Inc., a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced that Chief Executive Officer Saiid Zarrabian will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare company focused on value-based care, announced that the Company has entered into a definitive agreement with Sun Clinical Laboratories, under which ApolloMed will purchase controlling interests in Sun Labs for $4.0 million.

Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Tuesday, June 1, 2021 the Company entered into a global supply agreement for Vicineum™ drug substance and drug product with the Company’s partner in China, Qilu Pharmaceutical.

A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result.

Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 years BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp development pipeline U.S. commercial launch expected in the second half of 2021 in partnership with Amplity Health, marking the evolution of SCYNEXIS to a commercial-stage antifungal company